EU agency backs Pfizer leukaemia drug
LONDON Jan 18 (Reuters) - The European Medicines Agency on Friday recommended approval of Pfizer's new pill for a rare type of leukaemia, Bosulif, in a fresh boost for the U.S. drugmaker's cancer business.
Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
- Malaysian plane still missing; questions over false IDs |
- China draws 'red line' on North Korea, says won't allow war on peninsula
- Warning shots fired to turn monitors back from Crimea |
- Malaysian plane crashed off Vietnam coast: state media